Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials.

Saved in:
Bibliographic Details
Title: Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials.
Authors: Giménez-Arnau AM; Department of Dermatology, Hospital del Mar and Research Institute, Universitat Pompeu Fabra, Barcelona, Spain. Electronic address: anamariagimenezarnau@gmail.com., Zharkov A; Novartis Pharma AG, Basel, Switzerland., Yang B; Dermatology Hospital of Southern Medical University, Guangdong Provincial Dermatology Hospital, Guangzhou, China., Fukunaga A; Department of Dermatology, Division of Medicine for Function and Morphology of Sensory Organs, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan., Hide M; Department of Dermatology, Hiroshima City Hiroshima Citizens Hospital and Department of Dermatology, Hiroshima University, Hiroshima, Japan., Metz M; Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany., Mosnaim G; Division of Allergy and Immunology, Endeavor Health, Glenview, IL, USA., Staubach P; Department of Dermatology, University Medical Center Mainz, Germany., Gao XH; Department of Dermatology, The First Hospital of China Medical University, Shenyang, China., Jain V; Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada., Burciu A; Novartis Pharma AG, Basel, Switzerland., Cenni B; Novartis Pharma AG, Basel, Switzerland., Haemmerle S; Novartis Pharma AG, Basel, Switzerland., Kuruvilla M; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Huang S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Ledieu D; Novartis Pharma AG, Basel, Switzerland., Schuemann J; Novartis Pharma AG, Basel, Switzerland., Scosyrev E; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Schneider R; Novartis Pharma AG, Basel, Switzerland., Incera E; IQVIA RDS France, Saint-Ouen-sur-Seine, France., Lheritier K; Novartis Pharma AG, Basel, Switzerland., Tillmann HC; Novartis Pharma AG, Basel, Switzerland., Zouater H; Novartis Pharma AG, Basel, Switzerland., Saini S; Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA.
Source: The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2026 Jun 03. Date of Electronic Publication: 2026 Jun 03.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101597220 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2201 (Electronic) NLM ISO Abbreviation: J Allergy Clin Immunol Pract Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2213-2201
DOI:10.1016/j.jaip.2026.05.027